AstraZeneca sees 2017 revenues in line with 2013

AstraZeneca (AZN) believes it will return to growth "earlier than analyst consensus," and it expects 2017 revenues to be "broadly in line" with those of 2013. The company's earnings are being hit by patent expirations such as for cholesterol treatment Crestor.

AstraZeneca appears to base its forecast on its decision to buy Bristol-Myers Squibb's interests in their diabetes venture and on future drug launches.

AstraZeneca has treatments in 11 Phase III programs, almost double the number a year ago, and in 27 Phase II studies.

The company's comments come ahead of a presentation that CEO Pascal Soriot will give at the JP Morgan Healthcare Conference in San Francisco at 7.30 pm ET.

Shares +2% in London. (PR)

From other sites
Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs